Asset profile

stapokibart

Monoclonal antibody

Phase 3underway

Evidence outlook · registrational

Atopic Dermatitis: registrational readout pending

Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2026-08-30.

How the evidence outlook works ↗

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (1)
August 2026 (1)
Phase 3Atopic DermatitisActive not recruiting
Est. primary completion 2026-08-30 · NCT06495229 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (1)
February 2027 (1)
Phase 3Atopic DermatitisNot yet recruiting
Est. primary completion 2027-02 · NCT07106372 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2032 (1)
April 2032 (1)
Phase 2/3Chronic Obstructive Pulmonary DiseaseNot yet recruiting
Est. primary completion 2032-04-29 · NCT06547333 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.